Market Cap 143.34B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 7.87
Forward PE 8.07
Profit Margin 12.62%
Debt to Equity Ratio 0.66
Volume 19,328,500
Avg Vol 69,402,055
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 17%
Beta 0.46
Analysts Sell
Price Target $27.95

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
1iquid
1iquid Dec. 25 at 2:14 AM
💎 Liquid® Live Actionable Trade Asset: $PFE Contracts: $PFE January 15, 2027 $27 Calls Scale in: $1.35- $1.65 Scale out: $5.26-$9.02 Profit Potential : 276% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
reyofhope
reyofhope Dec. 24 at 8:37 PM
$PFE any good news and this can rocket up quicker then your buying finger . I'm staying here .
0 · Reply
Johnny_Lever
Johnny_Lever Dec. 24 at 8:09 PM
$PFE Tagging the rising trendline.
0 · Reply
taxplanr
taxplanr Dec. 24 at 7:53 PM
184 million person study of C19 jabs worse outcomes yet $BNTX $MRNA $PFE https://www.instagram.com/reel/DSpZfqQjXru/?igsh=ZXRjYXJqMHc0Nzcz
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Dec. 24 at 7:19 PM
$PFE - Guys, we should buy out Biohaven again 😆😆
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 6:44 PM
$PFE staring down a patent cliff — but this isn’t a capitulation story. Pfizer faces revenue pressure from 2026–2030 LOEs, yet it’s betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth 🚀 That shift in focus could redefine the company’s growth profile once the LOE overhang passes. See how Pfizer plans to navigate the patent cliff 👉 https://www.zacks.com/stock/news/2808723/pfes-oncology-obesity-pipeline-position-it-for-post-loe-growth?cid=sm-stocktwits-2-2808723-teaser-26268&ADID=SYND_STOCKTWITS_TWEET_2_2808723_TEASER_26268
0 · Reply
Typecheck
Typecheck Dec. 24 at 6:31 PM
$PFE 2025 is such a forgetful year for Pfizer. Hope 2026 will be better.
1 · Reply
Micheal_Pothead
Micheal_Pothead Dec. 24 at 6:05 PM
$PFE even on a half day we get an eod sell off
0 · Reply
asbpame
asbpame Dec. 24 at 6:04 PM
$PFE Merry Christmas to the bulls and....ok, for the bears, also, because is Christmas
0 · Reply
SPG565
SPG565 Dec. 24 at 5:55 PM
$PFE Closing Green only because it doesn't know the Market closes early today. Was probably waiting to go Red in a couple hours 😋😏
1 · Reply
Latest News on PFE
Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound

Dec 19, 2025, 11:45 AM EST - 5 days ago

Pfizer Isn't Dead Money, Pipeline Execution Can Spark A Rebound


Pfizer Stock Can Sink More. Here Is How

Dec 17, 2025, 2:36 PM EST - 7 days ago

Pfizer Stock Can Sink More. Here Is How


Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript

Dec 16, 2025, 2:39 PM EST - 8 days ago

Pfizer Inc. (PFE) Q4 2026 Guidance Call Transcript


Pfizer falls on disappointing guidance

Dec 16, 2025, 12:33 PM EST - 8 days ago

Pfizer falls on disappointing guidance


Here's why Pfizer is revising its revenue forecasts

Dec 16, 2025, 7:47 AM EST - 8 days ago

Here's why Pfizer is revising its revenue forecasts


Pfizer Declares First-Quarter 2026 Dividend

Dec 12, 2025, 12:00 PM EST - 12 days ago

Pfizer Declares First-Quarter 2026 Dividend


Pfizer: The Market Is Still Wrong About It

Dec 5, 2025, 9:00 AM EST - 19 days ago

Pfizer: The Market Is Still Wrong About It


Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters

Nov 30, 2025, 6:13 AM EST - 24 days ago

Pfizer: The Patent Cloud Is An Opportunity For Bargain Hunters


Final Trade: DAL, AXP, PFE, HMY

Nov 26, 2025, 6:20 PM EST - 4 weeks ago

Final Trade: DAL, AXP, PFE, HMY

AXP DAL HMY


Pfizer Crosses Below Key Moving Average Level

Nov 20, 2025, 4:05 PM EST - 4 weeks ago

Pfizer Crosses Below Key Moving Average Level


Pfizer: Is This Pharma Giant Finally A Bargain

Nov 19, 2025, 3:51 PM EST - 5 weeks ago

Pfizer: Is This Pharma Giant Finally A Bargain


Pfizer in $41.5 million settlement with Texas over ADHD drug

Nov 19, 2025, 10:31 AM EST - 5 weeks ago

Pfizer in $41.5 million settlement with Texas over ADHD drug


1iquid
1iquid Dec. 25 at 2:14 AM
💎 Liquid® Live Actionable Trade Asset: $PFE Contracts: $PFE January 15, 2027 $27 Calls Scale in: $1.35- $1.65 Scale out: $5.26-$9.02 Profit Potential : 276% ROI Blended Join 💎 Here: https://1iquid.com
0 · Reply
reyofhope
reyofhope Dec. 24 at 8:37 PM
$PFE any good news and this can rocket up quicker then your buying finger . I'm staying here .
0 · Reply
Johnny_Lever
Johnny_Lever Dec. 24 at 8:09 PM
$PFE Tagging the rising trendline.
0 · Reply
taxplanr
taxplanr Dec. 24 at 7:53 PM
184 million person study of C19 jabs worse outcomes yet $BNTX $MRNA $PFE https://www.instagram.com/reel/DSpZfqQjXru/?igsh=ZXRjYXJqMHc0Nzcz
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Dec. 24 at 7:19 PM
$PFE - Guys, we should buy out Biohaven again 😆😆
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 6:44 PM
$PFE staring down a patent cliff — but this isn’t a capitulation story. Pfizer faces revenue pressure from 2026–2030 LOEs, yet it’s betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth 🚀 That shift in focus could redefine the company’s growth profile once the LOE overhang passes. See how Pfizer plans to navigate the patent cliff 👉 https://www.zacks.com/stock/news/2808723/pfes-oncology-obesity-pipeline-position-it-for-post-loe-growth?cid=sm-stocktwits-2-2808723-teaser-26268&ADID=SYND_STOCKTWITS_TWEET_2_2808723_TEASER_26268
0 · Reply
Typecheck
Typecheck Dec. 24 at 6:31 PM
$PFE 2025 is such a forgetful year for Pfizer. Hope 2026 will be better.
1 · Reply
Micheal_Pothead
Micheal_Pothead Dec. 24 at 6:05 PM
$PFE even on a half day we get an eod sell off
0 · Reply
asbpame
asbpame Dec. 24 at 6:04 PM
$PFE Merry Christmas to the bulls and....ok, for the bears, also, because is Christmas
0 · Reply
SPG565
SPG565 Dec. 24 at 5:55 PM
$PFE Closing Green only because it doesn't know the Market closes early today. Was probably waiting to go Red in a couple hours 😋😏
1 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 5:44 PM
$PFE: Can Pfizer's pipeline offset looming patent expirations from 2026-2030? 🤔 💊 Upcoming LOE for key meds could hit revenues, but a robust R&D push, particularly in oncology, aims to sustain growth 🚀. With strategic acquisitions, new late-stage developments, and diversification into obesity, vaccines, and rare diseases, Pfizer eyes eight blockbuster oncology meds by 2030. Discover the full growth strategy here 👉 https://www.zacks.com/stock/news/2808723/pfes-oncology-obesity-pipeline-position-it-for-post-loe-growth?cid=sm-stocktwits-2-2808723-body-26267&ADID=SYND_STOCKTWITS_TWEET_2_2808723_BODY_26267
0 · Reply
sister
sister Dec. 24 at 5:28 PM
$MRNA $PFE can always get Cheaper . . . $NVO too
0 · Reply
reyofhope
reyofhope Dec. 24 at 5:28 PM
$PFE let this be the year for bourla and for us. What you all say??
0 · Reply
Micheal_Pothead
Micheal_Pothead Dec. 24 at 5:08 PM
$PFE this shit is so controlled
1 · Reply
Neahrain8
Neahrain8 Dec. 24 at 4:56 PM
0 · Reply
GPTX0041
GPTX0041 Dec. 24 at 4:40 PM
$PFE even the MM's should be bored to death, too
0 · Reply
GPTX0041
GPTX0041 Dec. 24 at 4:38 PM
$PFE buncha twit-sh*t
0 · Reply
hegdaom
hegdaom Dec. 24 at 4:29 PM
0 · Reply
GPTX0041
GPTX0041 Dec. 24 at 4:15 PM
$PFE Pfizer confirms death of shareholder--thinkin this would start doin better
0 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Dec. 24 at 4:10 PM
0 · Reply
ripztrip
ripztrip Dec. 24 at 4:02 PM
$AGIO 30 is the border line today! LFG $LLY $PFE $NVO $MRK
1 · Reply
LargeCapLord
LargeCapLord Dec. 24 at 3:54 PM
$PFE Downside protection weakens if discipline in balancing growth ambition with capital efficiency, with outcomes shaped by timing and discipline. Evidence of traction would justify structural re‑rating.
0 · Reply